Comparable stake leader
John Paul DeJoria
SEC ownership of Telomir Pharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001971532.
Disclosed value leader
Bay Shore Trust
Comparable rows
1/28
Latest evidence
30 Sep 2026
- Public ticker
- TELO on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
John Paul DeJoria
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
1 of 28
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
John Paul DeJoria
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Sep 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001971532
- Issuer location
- Miami, FL
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Telomir Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
John Paul DeJoria
Disclosed value leader
Bay Shore Trust
Comparable rows
1/28
Latest evidence
30 Sep 2026
13D/G
3/4/5
13F
Lead comparable stake: 5.2%
27 rows are not safely comparable across share classes.
13D/G row: John Paul DeJoria
Showing 1-8 of 28 holder rows.
Quick read
John Paul DeJoria leads the comparable SEC ownership view at 5.2%.
1 of 28 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens John Paul DeJoria's linked filing trail.
Comparable ownership
Top 1
John Paul DeJoria
5.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 28 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| John Paul DeJoria |
13D/G
John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust, and in his individual capacity
|
5.2%
Reported 13D/G
· 30 Jun 2026
|
$4,514,686
3,554,871 shares
|
+$393,536 | 30 Jun 2026 |
| Bay Shore Trust |
3/4/5
10%+ Owner
|
—
mixed-class rows
|
$20,414,715
5,631,721 shares
mixed-class rows
|
— | 21 Nov 2024 |
| MIRA PHARMACEUTICALS, INC. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$4,823,943
3,521,127 shares
|
— | 29 Sep 2025 |
| Erez Aminov |
3/4/5
CEO and Chairman, Director
|
—
mixed-class rows
|
$9,515,623
9,719,710 shares
mixed-class rows
|
— | 21 May 2026 |
| Christopher Chapman MD |
3/4/5
CEO & Chairman, Director
|
—
denominator unverified
|
$6,048,782
975,610 shares
|
— | 08 Feb 2024 |
| Craig Eagle |
3/4/5
Director
|
—
denominator unverified
|
$3,024,391
487,805 shares
|
— | 08 Feb 2024 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
—
denominator unverified
|
$1,936,367
1,613,639 shares
|
— | 30 Sep 2026 |
| Nathen Fuentes |
3/4/5
Chief Financial Officer
|
—
denominator unverified
|
$627,031
101,134 shares
|
— | 08 Feb 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
No eligible buy or sell activity is available for this window. No eligible Buy or Sell transactions are available in this dataset since 15 Nov 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-17 of 17 reporting-owner rows connected to Telomir Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
17
Largest Forms 3/4/5 holder
Bay Shore Trust
Net 12M change
$0
Latest report
03 Jun 2026
Recent insider transactions for Telomir Pharmaceuticals, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Erez Aminov | TELO | Non-Qualified Stock Options (right to buy) | Disposed to Issuer | -100% | -2,000,000 | 0 | 21 May 2026 | Direct | ||
| Erez Aminov | TELO | Non-Qualified Stock Options (right to buy) | Award | 2,000,000 | 2,000,000 | 21 May 2026 | Direct | |||
| Erez Aminov | TELO | Incentive Stock Options (right to buy) | Disposed to Issuer | -100% | -1,960,170 | 0 | 21 May 2026 | Direct | ||
| Erez Aminov | TELO | Incentive Stock Options (right to buy) | Award | 1,960,170 | 1,960,170 | 21 May 2026 | Direct | |||
| Matthew Pratt Whalen | TELO | Incentive Stock Options (right to buy) | Disposed to Issuer | -100% | -25,000 | 0 | 21 May 2026 | Direct | ||
| Matthew Pratt Whalen | TELO | Incentive Stock Options (right to buy) | Award | 25,000 | 25,000 | 21 May 2026 | Direct | |||
| Edward Clouston MacPherson | TELO | Incentive Stock Options (right to buy) | Disposed to Issuer | -100% | -25,000 | 0 | 21 May 2026 | Direct | ||
| Edward Clouston MacPherson | TELO | Incentive Stock Options (right to buy) | Award | 25,000 | 25,000 | 21 May 2026 | Direct | |||
| Matthew Paul del Giudice | TELO | Incentive Stock Options (right to buy) | Disposed to Issuer | -100% | -25,000 | 0 | 21 May 2026 | Direct | ||
| Matthew Paul del Giudice | TELO | Incentive Stock Options (right to buy) | Award | 25,000 | 25,000 | 21 May 2026 | Direct | |||
| Erez Aminov | TELO | Common Stock | Other | 7,319,710 | 7,319,710 | 22 Apr 2026 | Direct | |||
| Matthew Pratt Whalen | TELO | Non-Qualified Stock Options (right to buy) | Award | 50,000 | 50,000 | 16 Apr 2026 | Direct | |||
| Edward Clouston MacPherson | TELO | Non-Qualified Stock Options (right to buy) | Award | 50,000 | 50,000 | 16 Apr 2026 | Direct | |||
| Matthew Paul del Giudice | TELO | Non-Qualified Stock Options (right to buy) | Award | 50,000 | 50,000 | 16 Apr 2026 | Direct |
* marks a reported price that did not pass the local price check.